Research Article
Prognostic Impact of Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients
Table 4
Prognostic impact of LEF1 expression among two Gal.3 level groups.
| | LEF1high/Galectine.3 low (30) | Others (39) | | |
| | Age | 46.43 ± 16.49 | 45.21 ± 15.77 | 0.3 | 0.6 | | Performance status (PS 2&3) | 7 (41.2%) | 10 (58.8%) | 0.04 | 0.5 | | WBC × 109/L | 59.94 ± 66.87 | 83.39 ± 76.59 | −1.3 | 0.1 | | Hb gm/dl | 7.88 ± 2.04 | 8.1 ± 1.9 | −0.4 | 0.6 | | Plt × 109/L | 44.53 ± 34.24 | 61.76 ± 58.98 | 1.4 | 0.1 | | BM blast % | 62.37 ± 23.77 | 75.03 ± 20.23 | −2.3 | 0.02 | | Extramedullary disease | 5 (26.3%) | 14 (73.7%) | 3.1 | 0.065 | | FLT3-ITD mutated | 4 (21.1%) | 15 (78.9%) | 6.02 | 0.02 | | NPM1 mutated | 9 (45%) | 11 (55%) | 0.01 | 0.9 | | Favorable risk | 12 (70.6%) | 5 (29.4%) | 8.9 | 0.01 | | Intermediate risk | 10 (43.5% | 13 (65.5%) | | Poor risk | 4 (21.1%) | 15 (78.9%) | | Time to 1st CR | 29.50 ± 11.81 | 46.55 ± 2.53 | −5.04 | 0.001 | | Complete response | 28 (49.1%) | 29 (50.9%) | 4.2 | 0.055 | | Rebound thrombocytosis after induction | 20 (58.8%) | 14 (41.2%) | 6.4 | 0.01 | | Relapse/refractory | 15 (39.5%) | 23 (60.5%) | 0.5 | 0.4 |
|
|
